Indian API Manufacturer Called Out for Numerous Violations

Drug GMP Report
The FDA cited Reliance Life Sciences for a long list of deficiencies observed during an inspection of the API manufacturer’s facility in Navi Mumbai in December.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $157.00